Key facts
- This page summarizes Shane Barton's Form 3 filing for BioAge Labs, Inc. (BIOA).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 25 Sep 2024, 16:43.
Shane Barton - 25 Sep 2024 Form 3 Insider Report for BioAge Labs, Inc. (BIOA)
- Reporting relationship
- Principal Accounting Officer
- Issuer ticker
- BIOA
- Reported as of
- 25 Sep 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 25 Sep 2024, 16:43:18 UTC
- Prior SEC filing
- 09 Jun 2023
- Next SEC filing
- 10 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov A. Goldstein as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Shane Barton filed Form 3 for BioAge Labs, Inc. (BIOA) on 25 Sep 2024.
Change
- Previous filing in this sequence was filed on 09 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,890
- Exercise price
- $10.85
- Footnotes
- F1
BIOA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 28,277
- Exercise price
- $8.39
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option vested as to 1/4th of the total award on September 25, 2024, and thereafter shall vest as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F2
The option shall vest as to 1/48th of the total award monthly, with the first tranche vesting on October 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.